Urolithin A Bioavailability & Absorption

Urolithin A is unusual: it is not a compound you swallow in food, but one your gut bacteria are supposed to build for you. Whether it actually reaches your bloodstream depends less on how many pomegranates you eat and more on who lives in your gut. That single fact reshapes how you should think about dose, format, and why a direct supplement behaves so differently from the fruit.

Urolithin A is a postbiotic, not a nutrient

Most supplements deliver a molecule your body can use as-is: vitamin C is vitamin C the moment it dissolves. Urolithin A works differently. Pomegranates, walnuts, raspberries, strawberries and other foods do not contain meaningful urolithin A at all. What they contain are large polyphenols called ellagitannins, and their breakdown product, ellagic acid. Ellagic acid itself is poorly absorbed. Only after specific gut bacteria in the colon chemically remodel it, step by step, does urolithin A appear. In other words, urolithin A is a postbiotic: a compound produced by your microbiome from a dietary raw material, rather than something the plant hands you ready-made.

This matters for bioavailability because the rate-limiting step is not your digestive tract's ability to absorb urolithin A, which is reasonably good, but your microbiome's ability to manufacture it in the first place. If those bacteria are absent or scarce, you can eat ellagitannin-rich foods for years and still circulate very little urolithin A. To understand the mechanism and food sources in more depth, see our complete urolithin A guide and our overview of foods high in urolithin A.

The conversion bottleneck: why food is inconsistent

The bacteria capable of turning ellagic acid into urolithin A are a specialized minority. Research on urolithin metabolism sorts people into broad patterns, sometimes called metabotypes, based on which urolithins their gut can produce: some people make urolithin A efficiently, others make mostly downstream molecules, and a meaningful share make almost none. The exact species involved are still being mapped, but the practical takeaway is consistent across studies: production varies enormously from person to person, and it also shifts with age, antibiotic exposure, and overall gut composition.

The consequence is that dietary intake is an unreliable way to reach the amounts studied in clinical trials. Two people eating the identical bowl of berries can end up with radically different urolithin A levels in their blood. This is the core problem a direct supplement is designed to solve. We cover who does and does not convert well in are you a urolithin A producer?

What bioavailability actually means here

When researchers measure urolithin A bioavailability, they are tracking how much appears in the bloodstream and tissues after a dose. A few features are worth understanding:

It circulates mostly as conjugates

Once absorbed, urolithin A is rapidly processed by the liver and gut wall into conjugated forms (chiefly glucuronides, and some sulfates). This is normal for polyphenol-type compounds and is the same way your body handles many plant molecules. These conjugates are what circulate and what researchers typically measure. It is a sign the molecule is being absorbed and distributed, not a problem to be engineered away.

Direct dosing produces consistent exposure

The central advantage of supplementing urolithin A directly, rather than its precursors, is predictability. When you provide the finished molecule, you bypass the microbiome step entirely, so plasma levels become far more uniform across different people. Human pharmacokinetic work underpinning the clinical trials shows measurable, dose-related blood levels after direct oral urolithin A, which is precisely why trials use the direct compound rather than pomegranate extract.

What the human evidence shows (and its limits)

The clinical picture for urolithin A is built on direct supplementation, which is the relevant format for a bioavailability discussion.

Established human findings. The first-in-human study (Andreux et al., 2019, Nature Metabolism) reported that direct urolithin A was safe and well tolerated at doses up to 1,000 mg per day and produced a measurable mitochondrial gene-expression signature in muscle. In older adults, a roughly four-month trial (Liu, D'Amico et al., 2022, JAMA Network Open) found support for muscle endurance, measured as the number of contractions before fatigue. In middle-aged adults, a four-month trial (Singh et al., 2022, Cell Reports Medicine) tested 500 mg and 1,000 mg arms and reported support for muscle strength and exercise performance.

Newer human findings. A 2025 randomized trial (Nature Aging) over about 28 days reported support for immune-cell mitochondrial health in midlife adults. An 8-week 2024 trial in resistance-trained men (Journal of the International Society of Sports Nutrition) looked at endurance and recovery markers, and a 2025 trial in distance runners added further data in athletes.

Preclinical mechanism. The foundational work is preclinical: Ryu et al. (2016, Nature Medicine) showed urolithin A triggers mitophagy, extended lifespan in the worm C. elegans, and supported muscle function in rodents. This is animal and cell research, not human proof, but it explains the mechanism the human trials then probed.

Honest limitation. A 2024 systematic review (Ageing Research Reviews) concluded that the human evidence is still emerging: trials are relatively short and modest in size. The bioavailability advantage of direct dosing is well supported; the long-term outcome picture is still being built. Because several areas urolithin A touches are condition-adjacent, none of this is a treatment for any medical condition, and you should talk to your own doctor before starting, especially if you take medication or have a health condition.

Format: gummies, capsules, and powders

Across common formats, the decisive variable is the actual delivered dose, not the delivery vehicle. A capsule, a gummy, and a scoop of powder providing the same amount of the same tested urolithin A will give broadly similar exposure. Where formats differ is adherence and accuracy: an under-dosed or untested product is the real risk, not the shape of the pill. Two practical checks: confirm the label states the urolithin A amount per serving clearly, and confirm third-party testing. SOMA HEALTH uses a raspberry, sugar-free gummy at 1,000 mg across a 4-gummy serving specifically because a pleasant daily format supports the consistency that matters most. For a broader format comparison, see the best urolithin A gummies and our notes on how to take urolithin A.

Should you take it with food?

Urolithin A is a lipophilic (fat-friendly) molecule, and like many such compounds it is generally reasonable to take with a meal that contains some fat, which may aid absorption and is gentle on the stomach. The clinical trials were conducted with daily dosing, and the most important habit is simply taking it consistently at the same time each day rather than chasing a perfect window. If you are unsure how timing fits your routine or medications, your pharmacist or doctor is the right person to ask.

What the studied doses assume

The clinically studied range is 500 to 1,000 mg per day of direct urolithin A, with 1,000 mg sitting at the top of that range. Crucially, those trial doses assume the finished molecule is delivered directly, not generated from fruit. This is why comparing a milligram figure on a pomegranate-extract label to a trial dose of direct urolithin A can be misleading: the two are not interchangeable, because the extract still depends on your microbiome to perform the conversion. A direct 1,000 mg serving, like the SOMA HEALTH format, is built to match the upper end of the studied range regardless of your gut bacteria. You can read more in our urolithin A dosage guide.

*These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure, or prevent any disease. This guide is educational and is not a substitute for advice from a qualified healthcare provider.